[go: up one dir, main page]

AU2001255241A1 - Leishmania antigens for use in the therapy and diagnosis of leishmaniasis - Google Patents

Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Info

Publication number
AU2001255241A1
AU2001255241A1 AU2001255241A AU5524101A AU2001255241A1 AU 2001255241 A1 AU2001255241 A1 AU 2001255241A1 AU 2001255241 A AU2001255241 A AU 2001255241A AU 5524101 A AU5524101 A AU 5524101A AU 2001255241 A1 AU2001255241 A1 AU 2001255241A1
Authority
AU
Australia
Prior art keywords
leishmaniasis
diagnosis
therapy
leishmania antigens
leishmania
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255241A
Inventor
Ajay Bhatia
Antonio Campos-Neto
Rhea M. Coler
Davin C. Dillon
Peter Probst
Steven G Reed
Yasir A.W. Skeiky
John R. Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/551,974 external-priority patent/US6500437B1/en
Priority claimed from US09/565,501 external-priority patent/US6607731B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2001255241A1 publication Critical patent/AU2001255241A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001255241A 2000-04-14 2001-04-05 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis Abandoned AU2001255241A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/551,974 2000-04-14
US09/551,974 US6500437B1 (en) 1995-09-22 2000-04-14 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US09/565,501 2000-05-05
US09/565,501 US6607731B1 (en) 1995-09-22 2000-05-05 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US09/639,206 2000-08-14
US09/639,206 US6613337B1 (en) 1997-02-12 2000-08-14 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
PCT/US2001/011254 WO2001079276A2 (en) 2000-04-14 2001-04-05 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Publications (1)

Publication Number Publication Date
AU2001255241A1 true AU2001255241A1 (en) 2001-10-30

Family

ID=27415636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255241A Abandoned AU2001255241A1 (en) 2000-04-14 2001-04-05 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Country Status (10)

Country Link
US (1) US6613337B1 (en)
EP (2) EP1287026B1 (en)
AR (1) AR028333A1 (en)
AT (1) ATE310746T1 (en)
AU (1) AU2001255241A1 (en)
DE (1) DE60115230T2 (en)
ES (2) ES2391562T3 (en)
MX (1) MXPA02010173A (en)
PT (1) PT1681301E (en)
WO (1) WO2001079276A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053446B (en) 1999-05-13 2005-02-25 Wyeth Corp Adjuvant Combination Formulations
ATE383871T1 (en) * 2000-02-18 2008-02-15 Vlaams Interuniv Inst Biotech USE OF OPRI LIPOPROTEIN FROM PSEUDOMONAS AS TH1-INDUCING NATURAL ADJUVANT FOR HETEROLOGUE ANTIGENS
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
WO2007121184A2 (en) 2006-04-10 2007-10-25 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of leishmaniasis
CN101743016B (en) * 2007-07-13 2015-05-13 传染性疾病研究院 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
ES2528928T3 (en) * 2008-05-21 2015-02-13 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
CN102083853B (en) 2008-07-03 2014-09-17 传染性疾病研究院 Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
BRPI0900961B8 (en) * 2009-03-23 2021-07-13 Fundacao Oswaldo Cruz Leishmaniasis diagnostic methods and kit
RU2558233C2 (en) * 2009-07-13 2015-07-27 Лабораториос Лети, С.Л. Diagnostics of parasitic disease, such as leishmaniasis, with application of ribosomal protein extract (rpe)
WO2014091463A1 (en) * 2012-12-14 2014-06-19 Universidade Federal De Minas Gerais - Ufmg Method for producing leishmania recombinant proteins and use in a diagnostic kit and vaccine against leishmaniases
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
US20140356391A1 (en) * 2013-05-29 2014-12-04 Jose Antonio O'Daly Amino acid sequences for clinical remission of psoriasis and related diseases.
JP2016053535A (en) * 2014-09-04 2016-04-14 国立大学法人 東京大学 Testing reagent or kit for cutaneous leishmaniasis, and testing method of the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870006A (en) 1986-07-24 1989-09-26 Codon Antigenic material for a chagas' disease detection system
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
BR9507505A (en) 1994-04-22 1997-09-02 Corixa Corp Isolated dna molecule recombinant host cell expression vector method for preparing a polypeptide that stimulates a th1 immune response in peripheral blood mononuclear cells obtained from an individual infected with leishmania polypeptide method to assess a patient's ability to generate an immune response method to improve a cellular and / or humoral immune response to a patient's antigen method to stimulate antibody production in a
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5965142A (en) 1995-08-04 1999-10-12 Corixa Corporation Polypeptides and methods for the detection of L. tropica infection
US5834592A (en) 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5744593A (en) * 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5846748A (en) 1996-11-15 1998-12-08 The Council Of Scientific & Industrial Research Method for diagnosing visceral leishmaniasis in a patient by identification of a new key marker namely 9-O-acetylated sialoglycoconjugate
BR9807332A (en) 1997-02-12 2000-10-31 Corixa Corp Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
CN1158387C (en) * 1998-12-23 2004-07-21 C.B.F.莱蒂股份有限公司 Chimeric gene encoding the antigenic determinants of four proteins of L.INFANTUM

Also Published As

Publication number Publication date
EP1287026B1 (en) 2005-11-23
DE60115230D1 (en) 2005-12-29
AR028333A1 (en) 2003-05-07
ATE310746T1 (en) 2005-12-15
WO2001079276A3 (en) 2002-09-06
MXPA02010173A (en) 2003-06-04
EP1681301B1 (en) 2012-07-18
ES2255553T3 (en) 2006-07-01
EP1287026A2 (en) 2003-03-05
PT1681301E (en) 2012-10-26
US6613337B1 (en) 2003-09-02
EP1681301A1 (en) 2006-07-19
ES2391562T3 (en) 2012-11-27
DE60115230T2 (en) 2006-08-03
WO2001079276A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
PT1757606E (en) Xanthinderivatives for use as medical agents and the preparation thereof
AU2001236798A1 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU2002227184A1 (en) Methods for development and use of diagnostic and therapeutic agents
AU2002356530A1 (en) Medical devices comprising nanomaterials and therapeutic methods utilizing the same
AU6019898A (en) Devices for tissue repair and methods for preparation and use thereof
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2001255241A1 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU3159499A (en) Antigen preparation and use
AU2002220744A1 (en) T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy
AU2002305811A1 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU4014700A (en) Tuberculosis antigens and methods of use therefor
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU6835300A (en) Diagnostic kit and use thereof
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU3153100A (en) Gas analyser and the use thereof in medical diagnostics
AU2001289930A1 (en) Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes
AU2002228085A1 (en) Utilization of a claudin-4 ligand and conjugates thereof in the therapy and diagnosis of tumors
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
AU2003286850A1 (en) ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2001245693A1 (en) Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
AU2002364385A1 (en) Implantable device and the use thereof
AUPR556601A0 (en) Therapeutic and diagnostic molecules - II
GB9926811D0 (en) Combined rapid diagnosis and therapy